- Sampson, Timothy R;
- Challis, Collin;
- Jain, Neha;
- Moiseyenko, Anastasiya;
- Ladinsky, Mark S;
- Shastri, Gauri G;
- Thron, Taren;
- Needham, Brittany D;
- Horvath, Istvan;
- Debelius, Justine W;
- Janssen, Stefan;
- Knight, Rob;
- Wittung-Stafshede, Pernilla;
- Gradinaru, Viviana;
- Chapman, Matthew;
- Mazmanian, Sarkis K
Amyloids are a class of protein with unique self-aggregation properties, and their aberrant accumulation can lead to cellular dysfunctions associated with neurodegenerative diseases. While genetic and environmental factors can influence amyloid formation, molecular triggers and/or facilitators are not well defined. Growing evidence suggests that non-identical amyloid proteins may accelerate reciprocal amyloid aggregation in a prion-like fashion. While humans encode ~30 amyloidogenic proteins, the gut microbiome also produces functional amyloids. For example, curli are cell surface amyloid proteins abundantly expressed by certain gut bacteria. In mice overexpressing the human amyloid α-synuclein (αSyn), we reveal that colonization with curli-producing Escherichia coli promotes αSyn pathology in the gut and the brain. Curli expression is required for E. coli to exacerbate αSyn-induced behavioral deficits, including intestinal and motor impairments. Purified curli subunits accelerate αSyn aggregation in biochemical assays, while oral treatment of mice with a gut-restricted amyloid inhibitor prevents curli-mediated acceleration of pathology and behavioral abnormalities. We propose that exposure to microbial amyloids in the gastrointestinal tract can accelerate αSyn aggregation and disease in the gut and the brain.